secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001213900-25-107249
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma completes second dose cohort in EB103 trial; 100% CR rate
-------------------------------------------------------------------------------

- 100% complete response (CR) rate at Month 1 in all evaluable patients in second dose cohort of STARLIGHT-1 trial.
- All patients are high-risk, including one with CNS lymphoma; no treatment-related serious adverse events reported.
- DSMB will review cumulative data to determine Recommended Phase II Dose (RP2D) for expansion phase.
- EB103 is a CD19-redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell Non-Hodgkin's Lymphoma (NHL).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025107249/0001213900-25-107249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025107249/ea0264099-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-107249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer